BRPI0515794A - processos para avaliar pacientes com leucemia mielóide aguda - Google Patents

processos para avaliar pacientes com leucemia mielóide aguda

Info

Publication number
BRPI0515794A
BRPI0515794A BRPI0515794-3A BRPI0515794A BRPI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A BR PI0515794 A BRPI0515794 A BR PI0515794A
Authority
BR
Brazil
Prior art keywords
patient
processes
myeloid leukemia
therapy
acute myeloid
Prior art date
Application number
BRPI0515794-3A
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of BRPI0515794A publication Critical patent/BRPI0515794A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

''PROCESSOS PARA AVALIAR PACIENTE COM LEUCEMIA MIELóIDE AGUDA ''.apresentação invenção refere-se a processos para o tratamento cãncer preferencialmente de expressã o genetica e/o de marcadores moleculares de um paciente paradeterminar o estado e/ou prognóstico do paciente .A invenção fornece ainda processos de análise se um paciente náo reflátario provavelmente responde ao tratamento co inihidores (FTIS) e; opcionalmente ; outros agentes terapêuticos .Os processos tanbém são úteis para monitorar a terapia do paciente e para selecionar um curso de terapia .São fornecidos genes modulados em respostas ao tratamento com FTI esão utilizados na formulação dos perfis.
BRPI0515794-3A 2004-12-17 2005-12-19 processos para avaliar pacientes com leucemia mielóide aguda BRPI0515794A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US67011605P 2005-04-11 2005-04-11
US74118005P 2005-12-01 2005-12-01
PCT/US2005/046100 WO2006066240A2 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia

Publications (1)

Publication Number Publication Date
BRPI0515794A true BRPI0515794A (pt) 2008-08-05

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515794-3A BRPI0515794A (pt) 2004-12-17 2005-12-19 processos para avaliar pacientes com leucemia mielóide aguda

Country Status (9)

Country Link
EP (1) EP1836313A4 (pt)
JP (1) JP2008523822A (pt)
KR (1) KR20070099564A (pt)
AU (1) AU2005316291A1 (pt)
BR (1) BRPI0515794A (pt)
CA (1) CA2589055A1 (pt)
IL (1) IL183555A0 (pt)
MX (1) MX2007007401A (pt)
WO (1) WO2006066240A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (ko) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) 급성 골수성 백혈병 환자의 항암제 치료 반응성 예측용마커
JP2010516291A (ja) * 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病（ａｍｌ）の診断、予後及び治療のためのマイクロｒｎａに基づく方法及び組成物
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
JP2011520183A (ja) * 2008-04-25 2011-07-14 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ サンプルデータの分類
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011131246A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012007783A1 (en) * 2010-07-13 2012-01-19 Institut Gustave Roussy Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
KR101660322B1 (ko) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 ＮＰＭ1 유전자의 ｅｘｏｎ12 변이의 검출용 프로브 및 그 용도
KR101922761B1 (ko) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 급성 골수성 백혈병 진단을 위한 ｃ―Ｋｉｔ 돌연변이 실시간 정량 ＰＣＲ 분석법 및 이의 이용
CN116004819B (zh) * 2022-08-19 2025-10-31 安徽同科生物科技有限公司 AML相关的lncRNA标志物、检测试剂盒及方法在AML诊断与预后中的应用

Also Published As

Publication number Publication date
MX2007007401A (es) 2007-10-08
EP1836313A2 (en) 2007-09-26
JP2008523822A (ja) 2008-07-10
IL183555A0 (en) 2007-09-20
WO2006066240A2 (en) 2006-06-22
EP1836313A4 (en) 2010-06-30
AU2005316291A1 (en) 2006-06-22
WO2006066240A8 (en) 2006-09-08
WO2006066240A3 (en) 2008-07-17
KR20070099564A (ko) 2007-10-09
CA2589055A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
DE60238132D1 (de) Patientenklassifizierung
EP1488007A4 (en) PERFORMANCE OF GENE EXPRESSION IN BIOPTIC TUMOR TISSUE
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE60324925D1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
EP1913391A4 (en) QUANTITATIVE ASSAYS FOR PDGFR IN BODY FLUIDS
BRPI0503418A (pt) prognóstico para malignidade hematológica
DK1816214T3 (da) Fremgangsmåde og sammensætninger til perioperativ, genomisk profilering
EP1565582A4 (en) METHOD FOR IDENTIFYING BREAST CANCER RISK AND TREATMENTS THEREOF
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
ATE426162T1 (de) Verfahren zum untersuchen von kírperflussikeiten auf krebszellen sowie entsprechende analysekits
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
BRPI0502433A (pt) métodos para avaliação e tratamento de cáncer
ATE529743T1 (de) Verfahren und kits zur tumorigenizitätsdiagnose
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
MX2007007401A (es) Metodos para evaluar a pacientes con leucemia mieloide aguda.
DE602006013604D1 (de) Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
CY1105566T1 (el) Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση
BRPI0403291A (pt) Métodos para avaliação e tratamento de câncer
Tsurupa et al. Fibrinogen αC domains contain cryptic plasminogen and tPA binding sites

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.